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SCIENTIFIC OPINION 
Scientific Opinion on health claims already evaluated (ID 215, 568, 674, 
712, 1398, 1633, 1974, 4191, 4192, 4193, 4236, 4335, 4698, 4704) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to vitamin D and normal absorption of calcium; protein and growth or maintenance of 
muscle mass; protein and maintenance of normal bone; calcium and maintenance of normal bone; 
plant stanols and maintenance of normal blood cholesterol concentrations; alpha-linolenic acid (ALA) 
and maintenance of normal blood cholesterol concentrations; replacement of mixtures of saturated 
fatty acids (SFAs) as present in foods or diets with mixtures of polyunsaturated fatty acids (PUFAs) 
and maintenance of normal blood LDL-cholesterol concentrations; lactase and breaking down lactose; 
ethanol-water extract of Caralluma fimbriata and reduction in waist circumference; ethanol-water 
extract of Caralluma fimbriata and reduction of body weight; ethanol-water extract of Caralluma 
fimbriata and reduction of appetite; pectins and maintenance of normal blood cholesterol 
concentrations; chromium and maintenance of normal blood glucose concentrations; choline and 
maintenance of normal liver function. The scientific substantiation is based on the information 
provided by the Member States in the consolidated list of Article 13 health claims and references that 
EFSA has received from Member States or directly from stakeholders. 
The Panel concludes that the following health claims have already been assessed with a favourable 
outcome: 
 Vitamin D and normal absorption of calcium (ID 215). 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1499, EFSA-Q-2008-2369, adopted on 
25 March 2011. Question No EFSA-Q-2008-1002, EFSA-Q-2008-1355, EFSA-Q-2008-1461, EFSA-Q-2008-2135, 
EFSA-Q-2008-2707, EFSA-Q-2008-4902, EFSA-Q-2008-4903, EFSA-Q-2008-4904, EFSA-Q-2008-4946, EFSA-Q-
2010-00288, EFSA-Q-2010-00651, EFSA-Q-2010-00657, adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. 
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 Protein and growth or maintenance of muscle mass (ID 1398). 
 Protein and maintenance of normal bone (ID 4704). 
 Calcium and maintenance of normal bone (ID 4704). 
 Plant stanols and maintenance of normal blood cholesterol concentrations (ID 568). 
 Alpha-linolenic acid (ALA) and maintenance of normal blood cholesterol concentrations 
(ID 568). 
 Replacement of mixtures of saturated fatty acids (SFAs) as present in foods or diets with 
mixtures of polyunsaturated fatty acids (PUFAs) and maintenance of normal blood LDL-
cholesterol concentrations (ID 674, 4335). 
 Lactase and breaking down lactose (ID 1974). 
 Pectins and maintenance of normal blood cholesterol concentrations (ID 4236). 
 Chromium and maintenance of normal blood glucose concentrations (ID 4698). 
 Choline and maintenance of normal liver function (ID 712, 1633). 
The Panel concludes that the following health claims have already been assessed with an 
unfavourable outcome and that the references cited did not provide any additional scientific data 
which could be used to substantiate the claims: 
 Ethanol-water extract of Caralluma fimbriata and reduction in waist circumference 
(ID 4191). 
 Ethanol-water extract of Caralluma fimbriata and reduction of body weight (ID 4192). 
 Ethanol-water extract of Caralluma fimbriata and reduction of appetite (ID 4193). 
KEY WORDS 
Food, constituent, already evaluated, health claims. 
 
Health claims already evaluated 
 
3 EFSA Journal 2011;9(6):2203 
TABLE OF CONTENTS 
Summary .................................................................................................................................................. 1 
Table of contents ...................................................................................................................................... 3 
Background as provided by the European Commission .......................................................................... 4 
Terms of reference as provided by the European Commission ............................................................... 4 
EFSA Disclaimer...................................................................................................................................... 4 
Information as provided in the consolidated list ...................................................................................... 5 
Assessment ............................................................................................................................................... 5 
1. Characterisation of the food/constituent ........................................................................................ 5 
1.1. Vitamin D (ID 215) ................................................................................................................... 5 
1.2. Protein (ID 1398, 4704) ............................................................................................................ 5 
1.3. Calcium (ID 4704) .................................................................................................................... 5 
1.4. Plant stanols (ID 568) ............................................................................................................... 5 
1.5. Alpha-linolenic acid (ALA) (ID 568) ....................................................................................... 6 
1.6. Replacement of mixtures of saturated fatty acids (SFAs) as present in foods or diets with 
mixtures of polyunsaturated fatty acids (PUFAs) (ID 674, 4335) ............................................ 6 
1.7. Lactase (ID 1974) ..................................................................................................................... 6 
1.8. Ethanol-water extract of Caralluma fimbriata (ID 4191, 4192, 4193) .................................... 6 
1.9. Pectins (ID 4236) ...................................................................................................................... 6 
1.10. Chromium (ID 4698) ................................................................................................................ 7 
1.11. Choline (ID 712, 1633) ............................................................................................................. 7 
2. Relevance of the claimed effect to human health .......................................................................... 7 
2.1. Vitamin D and normal absorption of calcium (ID 215)............................................................ 7 
2.2. Protein and growth or maintenance of muscle mass (ID 1398) ................................................ 7 
2.3. Protein and maintenance of normal bone (ID 4704)................................................................. 8 
2.4. Calcium and maintenance of normal bone (ID 4704) ............................................................... 8 
2.5. Plant stanols and maintenance of normal blood cholesterol concentrations (ID 568) ............. 8 
2.6. Alpha-linolenic acid (ALA) and maintenance of normal blood cholesterol concentrations 
(ID 568) ..................................................................................................................................... 8 
2.7. Replacement of mixtures of saturated fatty acids (SFAs) as present in foods or diets with 
mixtures of polyunsaturated fatty acids (PUFAs) and maintenance of normal blood 
LDL-cholesterol concentrations (ID 674, 4335) ...................................................................... 8 
2.8. Lactase and breaking down lactose (ID 1974).......................................................................... 9 
2.9. Ethanol-water extract of Caralluma fimbriata and reduction in waist circumference 
(ID 4191) ................................................................................................................................... 9 
2.10. Ethanol-water extract of Caralluma fimbriata and reduction of body weight (ID 4192) ........ 9 
2.11. Ethanol-water extract of Caralluma fimbriata and reduction of appetite (ID 4193) ............... 9 
2.12. Pectins and maintenance of normal blood cholesterol concentrations (ID 4236) .................... 9 
2.13. Chromium and maintenance of normal blood glucose concentrations (ID 4698) .................. 10 
2.14. Choline and maintenance of normal liver function (ID 712, 1633) ....................................... 10 
Conclusions ............................................................................................................................................ 10 
Documentation provided to EFSA ......................................................................................................... 11 
References .............................................................................................................................................. 11 
Appendices ............................................................................................................................................. 13 
Glossary and Abbreviations ................................................................................................................... 22 
 
Health claims already evaluated 
 
4 EFSA Journal 2011;9(6):2203 
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
See Appendix A 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
See Appendix A 
EFSA DISCLAIMER 
See Appendix B 
Health claims already evaluated 
 
5 EFSA Journal 2011;9(6):2203 
INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
1.1. Vitamin D (ID 215)  
The food constituent that is the subject of the health claim is vitamin D. Vitamin D is a well 
recognised nutrient and is measurable in foods by established methods.  
The Panel considers that the food constituent, vitamin D, which is the subject of the health claim, is 
sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009a). 
1.2. Protein (ID 1398, 4704) 
The food constituent that is the subject of the health claims is protein.  
The Panel considers that the food constituent, protein, which is the subject of the health claims, is 
sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010a). 
1.3. Calcium (ID 4704) 
The food constituent that is the subject of the health claim is calcium. Calcium is a well recognised 
nutrient and is measurable in foods by established methods.  
The Panel considers that the food constituent, calcium, which is the subject of the health claim, is 
sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009b) 
1.4. Plant stanols (ID 568) 
The food constituent that is the subject of the health claim is plant stanols.  
The Panel considers that the food constituent, plant stanols, which is the subject of the health claim, is 
sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010b). 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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1.5. Alpha-linolenic acid (ALA) (ID 568) 
The food constituent that is the subject of the health claim is “omega-3 fatty acids”.  
From the proposed conditions of use and the references provided, the Panel assumes that the food 
constituent, which is the subject of the health claim, is alpha-linolenic acid (ALA). 
The Panel considers that the food constituent, alpha-linolenic acid (ALA), which is the subject of the 
health claim, is sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2009c). 
1.6. Replacement of mixtures of saturated fatty acids (SFAs) as present in foods or diets 
with mixtures of polyunsaturated fatty acids (PUFAs) (ID 674, 4335) 
The food constituent that is the subject of the health claims is “polyunsaturated fatty acids”. 
In the context of the proposed wordings, the Panel assumes that the food constituent, which is the 
subject of the health claim, is saturated fatty acids (SFAs), which should be replaced by 
cis-polyunsaturated fatty acids (cis-PUFAs) in foods or diets in order to obtain the claimed effect.  
The Panel considers that the food constituent, saturated fatty acids as present in foods or diets, and the 
food constituent, mixtures of cis-PUFAs, which should replace SFAs in foods, and which are the 
subject of the health claim, are sufficiently characterised (EFSA Panel on Dietetic Products Nutrition 
and Allergies (NDA), 2011a). 
1.7. Lactase (ID 1974) 
The food constituent that is the subject of the health claim is lactase (beta-D-galactohydrolase). 
The Panel considers that the food constituent, lactase, which is the subject of the health claim, is 
sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009d). 
1.8. Ethanol-water extract of Caralluma fimbriata (ID 4191, 4192, 4193) 
The food constituent that is the subject of the health claims is an ethanol-water extract of Caralluma 
fimbriata. 
From the proposed conditions of use, the Panel assumes that the ethanol-water extract of Caralluma 
fimbriata is identical to the food/constituent (Slimaluma
®
) submitted under Article 13.5 of Regulation 
(EC) No 1924/2006 (Question No EFSA-Q-2010-00027, EFSA-Q-2010-00028, EFSA-Q-2010-00029, 
EFSA-Q-2010-00030, EFSA-Q-2010-00031). 
The Panel considers that the food constituent, ethanol-water extract of Caralluma fimbriata, which is 
the subject of the health claims, is sufficiently characterised (EFSA Panel on Dietetic Products 
Nutrition and Allergies (NDA), 2010c, 2010d, 2010e). 
1.9. Pectins (ID 4236) 
The food constituent that is the subject of the health claim is pectins.  
The Panel considers that the food constituent, pectins, which is the subject of the health claim, is 
sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010f). 
Health claims already evaluated 
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1.10. Chromium (ID 4698) 
The food that is the subject of the health claim is “Saccaromyces cerevisiae-brewer’s yeast”. 
From the references provided the Panel assumes that the food which is the subject of the health claim 
is chromium-enriched Saccharomyces cerevisiae, as a source of trivalent chromium Cr(III). Trivalent 
chromium is a well recognised nutrient and is measurable in foods by established methods.  
The Panel considers that the food constituent, trivalent chromium, which is the subject of the health 
claim, is sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 
2010g). 
1.11. Choline (ID 712, 1633) 
The food that is the subject of the health claims is “phospholipids (phosphatidyl choline, phosphatidyl 
ethanolamine, phosphatidyl inositol, lysophosphatidyl cholin)”. 
Phospholipids are a major component of all cell membranes. Most phospholipids contain a 
diglyceride, a phosphate group, and a simple organic molecule such as choline.  
From the conditions of use, the Panel assumes that the food, which is the subject of the health claim, 
is phosphatidylcholine, and that the food constituent responsible for the claimed effect is choline. 
Choline is measurable in foods by established methods. 
The Panel considers that the food constituent, choline, which is the subject of the health claim, is 
sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011b) 
2. Relevance of the claimed effect to human health 
2.1. Vitamin D and normal absorption of calcium (ID 215) 
The claimed effect is “vitamin D3 enhances the calcium-absorption from the gut by inducing 
formation of calcium-binding proteins within the small intestinal mucosa”. The Panel assumes that the 
target population is the general population. 
A claim on vitamin D and absorption of calcium and phosphorus and maintenance of normal blood 
calcium concentrations has already been assessed with a favourable outcome (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2009a). 
2.2. Protein and growth or maintenance of muscle mass (ID 1398) 
The claimed effect is “contribution to the assembly of muscles”. The Panel assumes that the target 
population is the general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the growth 
or maintenance of muscle mass.  
A claim on protein and growth or maintenance of muscle mass has already been assessed with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010a). 
Health claims already evaluated 
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2.3. Protein and maintenance of normal bone (ID 4704) 
The claimed effect is “yogurt is a source of calcium and proteins, indispensable for bone development, 
mineralization, density and strength”. The Panel assumes that the target population is the general 
population. 
A claim on protein and maintenance of normal bone has already been assessed with a favourable 
outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010a). 
2.4. Calcium and maintenance of normal bone (ID 4704) 
The claimed effect is “yogurt is a source of calcium and proteins, indispensable for bone development, 
mineralization, density and strength”. The Panel assumes that the target population is the general 
population. 
A claim on calcium and maintenance of normal bone has already been assessed with a favourable 
outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009b). 
2.5. Plant stanols and maintenance of normal blood cholesterol concentrations (ID 568) 
The claimed effect is “cardiovascular system”. The Panel assumes that the target population is the 
general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
maintenance of normal blood cholesterol concentrations.  
A claim on plant sterols and plant stanols and maintenance of normal blood cholesterol concentrations 
has already been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and 
Allergies (NDA), 2010b). 
2.6. Alpha-linolenic acid (ALA) and maintenance of normal blood cholesterol 
concentrations (ID 568) 
The claimed effect is “cardiovascular system”. The Panel assumes that the target population is the 
general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
maintenance of normal blood cholesterol concentrations.  
A claim on ALA and maintenance of normal blood cholesterol concentrations has already been 
assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2009c). 
2.7. Replacement of mixtures of saturated fatty acids (SFAs) as present in foods or diets 
with mixtures of polyunsaturated fatty acids (PUFAs) and maintenance of normal 
blood LDL-cholesterol concentrations (ID 674, 4335) 
The claimed effect is “cardiovascular system”. The Panel assumes that the target population is the 
general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal blood LDL-cholesterol concentrations. 
Health claims already evaluated 
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A claim on the replacement of mixtures of SFAs with cis-MUFAs and/or cis-PUFAs in foods or diets 
and maintenance of normal blood LDL-cholesterol concentrations has already been assessed with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011a). 
2.8. Lactase and breaking down lactose (ID 1974) 
The claimed effect is “lactose digestion”. The target population is individuals whose own lactase 
production is insufficient for breaking down lactose. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to breaking down lactose (i.e. enzymatic hydrolysis of lactose).  
A claim on lactase and breaking down lactose has already been assessed with a favourable outcome 
(EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009d). 
2.9. Ethanol-water extract of Caralluma fimbriata and reduction in waist circumference 
(ID 4191) 
The claimed effect is “helps reduce size of waist”. The Panel assumes that the target population is 
individuals who wish to reduce their waist circumference. 
A claim on ethanol-water extract of Caralluma fimbriata and a reduction in waist circumference, if 
accompanied by an improvement in the adverse health effects of an excess abdominal fat, has already 
been assessed with an unfavourable outcome (EFSA Panel on Dietetic Products Nutrition and 
Allergies (NDA), 2010e), and the references cited for this claim did not provide any additional 
scientific data that could be used to substantiate the claim.  
2.10. Ethanol-water extract of Caralluma fimbriata and reduction of body weight (ID 4192) 
The claimed effect is “helps reduce body weight”. The Panel assumes that the target population is 
overweight individuals in the general population who wish to reduce their body weight.  
A claim on ethanol-water extract of Caralluma fimbriata and reduction of body weight, has already 
been assessed with an unfavourable outcome (EFSA Panel on Dietetic Products Nutrition and 
Allergies (NDA), 2010c), and the references cited for this claim did not provide any additional 
scientific data that could be used to substantiate the claim.  
2.11. Ethanol-water extract of Caralluma fimbriata and reduction of appetite (ID 4193) 
The claimed effect is “helps reduce appetite”. The Panel assumes that the target population is the 
general population.  
A claim on ethanol-water extract of Caralluma fimbriata and a reduction of appetite leading to a 
reduction in subsequent energy intake, has already been assessed with an unfavourable outcome 
(EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010d), and the references cited 
for this claim did not provide any additional scientific data that could be used to substantiate the 
claim.  
2.12. Pectins and maintenance of normal blood cholesterol concentrations (ID 4236) 
The claimed effect is “weight management and lipid control (via fiber)”. The Panel assumes that the 
target population is the general population.  
Health claims already evaluated 
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No references on weight management were provided in the consolidated list. In the context of the 
proposed wordings, the Panel assumes that the claimed effect refers to the maintenance of normal 
blood cholesterol concentrations.  
A claim on pectins and maintenance of normal blood cholesterol concentrations has already been 
assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2010f). 
2.13. Chromium and maintenance of normal blood glucose concentrations (ID 4698) 
The claimed effect is “sanguine health”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
maintenance of normal blood glucose concentrations. 
A claim on trivalent chromium and maintenance of normal blood glucose concentrations has already 
been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2010g).  
2.14. Choline and maintenance of normal liver function (ID 712, 1633) 
The claimed effect is “liver health”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the maintenance of normal liver function.  
A claim on choline and maintenance of normal liver function has already been assessed with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011b) 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The following health claims have already been assessed with a favourable outcome: 
vitamin D and normal absorption of calcium (ID 215); protein and growth or maintenance of 
muscle mass (ID 1398); protein and maintenance of normal bone (ID 4704); calcium and 
maintenance of normal bone (ID 4704); plant stanols and maintenance of normal blood 
cholesterol concentrations (ID 568); alpha-linolenic acid (ALA) and maintenance of normal 
blood cholesterol concentrations (ID 568); replacement of mixtures of saturated fatty acids 
(SFAs) as present in foods or diets with mixtures of polyunsaturated fatty acids (PUFAs) and 
maintenance of normal blood LDL-cholesterol concentrations (ID 674, 4335); lactase and 
breaking down lactose (ID 1974); pectins and maintenance of normal blood cholesterol 
concentrations (ID 4236); chromium and maintenance of normal blood glucose concentrations 
(ID 4698); choline and maintenance of normal liver function (ID 712, 1633). 
 The following health claims have already been assessed with an unfavourable outcome and 
the references cited did not provide any additional scientific data that could be used to 
substantiate the claims: ethanol-water extract of Caralluma fimbriata and reduction in waist 
circumference (ID 4191); ethanol-water extract of Caralluma fimbriata and reduction of body 
weight (ID 4192); ethanol-water extract of Caralluma fimbriata and reduction of appetite (ID 
4193). 
Health claims already evaluated 
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DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1002, 
EFSA-Q-2008-1355, EFSA-Q-2008-1461, EFSA-Q-2008-1499, EFSA-Q-2008-2135, EFSA-Q-2008-
2369, EFSA-Q-2008-2707, EFSA-Q-2008-4902, EFSA-Q-2008-4903, EFSA-Q-2008-4904, EFSA-Q-
2008-4946, EFSA-Q-2010-00288, EFSA-Q-2010-00651, EFSA-Q-2010-00657). The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to health claims already evaluated, including conditions of 
use from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
215 Vitamin D3 Vitamin D3 steigert die 
Resorption von Calcium 
aus dem Darm, indem es 
in der 
Dünndarmschleimhaut 
die Bildung eines 
calciumbindenden 
Proteins induziert 
Clarification provided 
vitamin D3 enhances the 
Calcium-absorption from 
the gut by inducing 
formation of calcium-
binding prteins within 
the small intestinal 
mucosa 
[In german : ] Vitamin D3 steigert die 
Resorption von Kalzium aus dem 
Darm. 
Clarification provided 
Vitamin D3 can increase absorption 
of calcium from the gut. 
Conditions of use 
- None provided 
ID Food or Food constituent Health Relationship Proposed wording 
568 Plant stanol + omega-3 fatty 
acids 
Cardiovascular system Contains/enriched with plant stanol, 
which effectively reduces cholesterol. 
Omega-3 fatty acids are good for the 
heart. 
Symbol included in the claim: 
Benecol (see previous) 
Conditions of use 
- Vegetable fat spreads with 32% fat and containing. 7.2 g/100 g, 0.4 g/serving (1 tsp) of plant 
stanols and 4 g /100 g, 0.2 g/serving of omega-3 fatty acids/alpha-linoleic acid.Omega-3 
fatty acids and plant stanol are not altered during processing. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
674 Polyunsaturated fatty acids  Cardio-vascular system Replacement of saturated fatty acids 
by polyunsaturated fatty acids in the 
diet is beneficial for the blood total 
cholesterol and LDL cholesterol 
levels. 
Conditions of use 
- 6-10 energy % (around 13-22 g/day). The product shall contain a significant amount of 
PUFA compared to the recommended daily allowance. Health claims can be applied on 
foods complying with requirements of nutrition claims. High polyunsaturated fatty acids”  
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Comments from Member States 
This health relationship can be classified as a general dietary guideline, but as a part of 
commercial communication it should be handled under Reg. 1924/2006/EK. 
ID Food or Food constituent Health Relationship Proposed wording 
712 Phospholipids (Phosphatidyl 
choline, Phosphatidyl 
ethanolamine, Phosphatidyl 
inositol, Lysophosphatidyl 
cholin) 
Liver health 
Clarification provided 
Phospholipids have 
positive effects on the 
parameters of hepatocyte 
integrity: 
Improve enzymatic 
function of liver 
Improve detoxifying 
function of liver 
Contributes to the normal functioning 
of the liver 
Conditions of use 
- Min 1 g per day 
ID Food or Food constituent Health Relationship Proposed wording 
1398 Milch 
Clarification provided 
milk - high quality proteins 
Beitrag zum 
Muskelaufbau 
Clarification provided 
contribution to the 
assembly of muscles 
[In german : ] Sportler sollten auf eine 
eiweißreiche Ernährung achten - vor 
allem nach dem Sport. Hochwertige 
Proteine aus Molkegetränke, 
Buttermilch oder fettarmen 
Milchprodukten sorgen dafür, dass 
die Muskeln schnell wieder aufgebaut 
werden. 
Clarification provided 
Sportsmen should look after an 
albuminous alimentation maily after 
sport activities. High quality proteins 
from whey drinks, buttermilk or low-
fat milk products care for a rapid 
assembly of muscles 
Conditions of use 
- Milch ist meine Stärke im Sinne von Schönheit / Leistungsfähigkeit/ Energie/ Intelligenz  
ID Food or Food constituent Health Relationship Proposed wording 
1633 Phospholidips (Phosphatidyl 
choline, Phosphatidyl 
ethanolamine, Phosphatidyl 
inositol, Lysophosphatidyl 
cholin) 
Liver health 
Clarification provided 
Liver health 
Clarification:  
Phospholipids have 
positive effects on the 
parameters of hepatocyte 
integrity 
Contributes to the normal functioning 
of the liver 
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Conditions of use 
- Food supplement with phospholipid content of 2500mg/100 g = dose. This is an animal 
lecithin water emulsion derived from the brain tissue of domestic pig. Active ingredients 
include linoleic acid (= fatty acid), alpha-linoleic acid (= fatty acid) and choline (= 
phosphatidylcholine). 
- Min 1 g per day 
ID Food or Food constituent Health Relationship Proposed wording 
1974 Lactase (bêta D 
galactohydrolase) as food 
complement 
 
Lactose digestion 
Clarification provided 
enhance gastrointestinal 
digestion of lactose 
Contributes to have better lactose 
digestion  
Conditions of use 
- Oral ingestion (9900 FCC/50g lactose) before consumption of lactose containing product. 
remark: activity expressed in FCC according to method defined in Food Chemical Codex 
ID Food or Food constituent Health Relationship Proposed wording 
4191 Water-ethanol extract of 
Caralluma fimbriata 
Helps reduce size of 
waist 
Natures solution to help reduce you 
reduce your waist size 
Conditions of use 
- The recommended dosage for the water-ethanol extract of Caralluma fimbriata (Gencor 
Pacific) is 1000 (2 x 500) mg per day. No adverse effects reported. Women who are 
pregnant or planning a pregnancy should consult a healthcare professional before taking any 
food supplements.  
ID Food or Food constituent Health Relationship Proposed wording 
4192 
 
Water-ethanol extract of 
Caralluma fimbriata 
Helps reduce body 
weight 
Natures solution to help reduce your 
body weight 
Conditions of use 
- The recommended dosage for the water-ethanol extract of Caralluma fimbriata (Gencor 
Pacific) is 1000 (2 x 500) mg per day. No adverse effects reported. Women who are 
pregnant or planning a pregnancy should consult a healthcare professional before taking any 
food supplements.  
ID Food or Food constituent Health Relationship Proposed wording 
4193 Water-ethanol extract of 
Caralluma fimbriata 
Helps reduce appetite Natures solution to help reduce your 
appetite as part of a healthy lifestyle 
Conditions of use 
- The recommended dosage for the water-ethanol extract of Caralluma fimbriata (Gencor 
Pacific) is 1000 (2 x 500) mg per day. No adverse effects reported. Women who are 
pregnant or planning a pregnancy should consult a healthcare professional before taking any 
food supplements.  
ID Food or Food constituent Health Relationship Proposed wording 
4236 Pectine de pomme : Dry 
extract of Pirus malus (apple 
pectin) 
Weight management and 
lipid control (via fiber) 
Fruits pectin helps to manage appetite 
(satiety-feeling enhancer effect). 
Fruits pectin helps to improve bowel 
transit.  
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Fruits pectin helps to improve lipids 
control (total and LDL-cholesterol). 
Fruits pectin takes part in the 
regulation of the absorption of fat. 
Conditions of use 
- the equivalent of 20 g substance 
ID Food or Food constituent Health Relationship Proposed wording 
4335 Polyunsaturated fatty acids  Cardio-vascular system Replacement of saturated fatty acids 
by polyunsaturated fatty acids in the 
diet is beneficial for the blood total 
cholesterol and LDL cholesterol 
levels. 
Conditions of use 
- 6-10 energy % (around 13-22 g/day).;The product shall contain a significant amount of 
PUFA compared to the recommended daily allowance. Health claims can be applied on 
foods complying with requirements of nutrition claims "High polyunsaturated fatty acids" 
ID Food or Food constituent Health Relationship Proposed wording 
4698 Saccaromyces cerevisiae-
Brewer’s Yeast 
Sanguine health Help to maintain a normal blood 
glucose level as part of a healthy life 
style / Contributes to normal glucose 
– insulin metabolism 
Conditions of use 
- Powder / 200 mg brewer’s yeast / 1 tablet 3 times per day 
ID Food or Food constituent Health Relationship Proposed wording 
4704 yogurt-calcium and proteins yogurt is a source of 
calcium and proteins, 
indispensable for bone 
development, 
mineralization, density 
and strength 
Yogurt is a source of calcium and 
proteins, indispensable for strong 
bones 
Conditions of use 
- source of protein and Calcium, as per the annex to Regulation CE 1924/2006 
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GLOSSARY AND ABBREVIATIONS 
ALA  Alpha-linolenic acid  
LDL  Low density lipoprotein 
MUFA  Monounsaturated fatty acid  
PUFA  Polyunsaturated fatty acid 
SFA  Saturated fatty acid 
